Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Jasper Therapeutics to Host Investor Conference Call and Webcast on January 31, 2023 | ||
By: GlobeNewswire - 30 Jan 2023 | Back to overview list |
|
REDWOOD CITY, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, announced today that it will host an investor conference call and webcast to provide a corporate update on Tuesday, January 31 from 8:30 am – 9:30 am Eastern Time. The conference call will be hosted by the Jasper management team and can be accessed by dialing 1-877-407-4018 (toll-free domestic) or 1-201-689-8471 (international) or by clicking on this link and requesting a return call. The live webcast, which will include presentation slides, may be accessed via the investor relations section of the Jasper website at www.jaspertherapeutics.com. A replay of the webcast will be available for 90 days. About Jasper Jasper is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic mast and stem cell diseases such as chronic urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) and as a conditioning agent for stem cell transplants for rare diseases such as sickle cell disease (SCD), Fanconi anemia (FA) and severe combined immunodeficiency (SCID). To date, briquilimab has a demonstrated efficacy and safety profile in over 130 dosed subjects and healthy volunteers, with clinical outcomes as a conditioning agent in SCID, acute myeloid leukemia (AML), MDS, FA, and SCD. In addition, briquilimab is being advanced as a transformational non-genotoxic conditioning agent for gene therapy. Contacts: John Mullaly (investors) Jeet Mahal (investors) Lauren Barbiero (media) |
||
|
||
Copyright 2023 GlobeNewswire | Back to overview list |